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Objectives. To review current evidence for the effectiveness of smoking cessation interventions in cardiovascular patient
populations.
Design and materials. Studies were obtained from systematic reviews of the Cochrane Tobacco Addiction Review
Group. Twelve Cochrane reviews related to secondary prevention in a variety of populations were used to extract eligible
studies. Studies were eligible when they considered smokers diagnosed with symptomatic cardiovascular disease.
Methods. Data concerning the comparison between the intervention of interest and a placebo or standard treatment group
were derived from eligible papers. Based on these data, Absolute Risk Reduction figures were calculated to express the
effectiveness of each intervention on smoking cessation.
Results. We found 12 studies examining smoking cessation interventions in cardiovascular patients. Five studies reported
significant results. No evidence was found for Nicotine Replacement Therapy or other pharmacology to be effective, neither
for self-help materials, group, individual or telephone counseling. There is limited evidence for physician’s advice and nurse-
delivered interventions to be effective.
Conclusions. Smoking cessation studies in cardiovascular patients are scarce. The available studies show very limited
effects. The reasons for the lack of success of smoking cessation strategies in these patients remain unclear. Further research is
needed to find effective cessation strategies for patients with cardiovascular diseases.
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Introduction
The long-term cardiovascular health risks associated
with cigarette smoking are well established.1,2 Smok-
ing is the most important preventable contributor to
premature death, disability, and unnecessary health
expense in many countries. It is a major risk factor for
all manifestations of coronary artery disease (CAD),
stroke, and peripheral vascular disease.1,3 – 9 Cigarette
smoking is estimated to have been responsible for
about 21% of all deaths in the United States in 1990:
43% of these deaths as a result of cardiovascular
diseases (CVD).6,10 – 12 Dutch figures are comparable:
in 2000, 32% died because of CVD due to smoking.7 It
is plausible that in other western countries similar
figures will be found.
Not only in primary, but also in secondary preven-
tion smoking cessation is highly relevant. Patients
with CVD who quit smoking, reduce their risk of
cardiovascular events immediately and significantly
when compared to those who continue smoking.13,14
Coronary heart disease risk (CHD) is reduced by more
than 50% as quickly as one year after smoking
cessation, and within several years of abstinence the
CHD risk of former smoking patients approaches
those of life long abstainers.6,14 – 16 In a study where
patients underwent coronary artery bypass surgery,
smoking cessation after surgery was an important
independent predictor of a lower risk of death and
coronary reintervention during the 20-year follow-up.
The estimated benefit of survival for quitters increased
from 3% at 5 years to 14% at 15 years.17 The benefits of
smoking cessation on stroke risk are also evident. In
the Framingham Heart Study cohort of more than 4000
men and women,18 stroke risk decreased significantly
by two years and was at the level of nonsmokers by
five years after cessation of cigarette smoking. Another
Eur J Vasc Endovasc Surg 26, 467–475 (2003)
doi: 10.1016/S1078-5884(03)00347-2, available online at http://www.sciencedirect.com on
*Corresponding author. D. A. Legemate, Department of Surgery
(G411), Academic Medical Center, P. O. Box 22700, Amsterdam 1100
DE, The Netherlands.
1078–5884/050467 + 09 $35.00/0 q 2003 Elsevier Ltd. All rights reserved.
study19 showed that the excess risk of strokes among
former smoking female patients largely disappeared
from 2 to 4 years after cessation. Finally, smoking
cessation in patients with peripheral arterial disease
yields significant reductions of pain at rest and of risk
of intermittent claudication, subsequent myocardial
infarction, cardiac death, and total mortality.14,20
The extent of harm caused by tobacco and the rapid
decline of risk after quitting smoking makes the
discouragement of smoking a high priority for
physicians. Evidence, however, suggests that such
preventive action is usually not taken, despite the
availability of cost effective smoking cessation inter-
ventions.6,12,21 Over the past 15–20 years, evidence
demonstrating the effectiveness of smoking cessation
programs is accumulating in clinical medicine.8,22 – 24
In smoking cessation studies, researchers have paid
attention to the effectiveness of interventions in
different patient groups. Few studies included patients
with different manifestations of CVD, however. More-
over, these few studies focused on specific cardiovas-
cular patient groups such as hospitalized patients or
patients suffering from CHD.8,25 – 27 Results of studies
focusing on specific cardiovascular patient groups
cannot be generalized to the overall cardiovascular
patient population. Consequently, the purpose of this
paper is to review existing secondary prevention
smoking cessation methods and discuss their effec-
tiveness for the population of cardiovascular patients
at large.
Methods
Search strategy
Our review is based on reviews conducted by the
Cochrane Tobacco Addiction Review Group (http://www.
update-software.com/clibng/cliblogon.htm), further
referred to as the Cochrane Reviews. Each Cochrane
Review presents the evidence and conclusions for a
particular treatment. Thirty systematic smoking cessa-
tion reviews are available covering primary and
secondary prevention, pharmacological interventions,
behavioral interventions, complementary therapies,
interventions in specific groups and settings, inter-
ventions by specific providers and other interventions
to assist smoking cessation. Participants are not only
healthy volunteers but also patients with a variety of
health problems.
These Cochrane Reviews include papers describing
randomized (clinical) trials with a minimum follow-
up of 6 months. They use the strictest available criteria
to define abstinence from smoking as an outcome.
Hence, sustained abstinence is preferred over point
prevalence rates, and biochemical validated absti-
nence reports over self-reported abstinence. Addition-
ally, analyses are based on the ‘intention to treat’
principle: all participants, lost to follow-up after
randomization, are assumed to smoke at 6–12 months.
Our selection took place in August of 2002. We used
the latest versions of the Cochrane Reviews. Cochrane
Reviews concerning primary prevention, adolescents
or children (,18), workplace or community interven-
tions, mass media or training programs for health
professionals were excluded. This first selection
procedure resulted in 12 Cochrane Reviews related
to secondary prevention in a variety of patient
populations. All papers used in these reviews were
further screened for eligibility for this study. Papers
were eligible when they involved smokers with
symptomatic CVD, irrespective of their initial level
of nicotine dependency or the setting from which they
were recruited. Studies were excluded when no data
were provided to calculate the effect of an interven-
tion28 or when data concerning cardiovascular
patients could not be distillated from study groups
that consisted of a mix of patients with both
cardiovascular and other diseases.29 – 32
Analyses
From each eligible study, we obtained data of the
comparison between the intervention of interest and
the placebo or standard treatment group. When no
such ‘control’ group was available, we compared the
intervention group with the least intensive treatment
instead. Based on these data, Absolute Risk Reduction
(ARR) figures were calculated to express the effective-
ness of each intervention on smoking cessation in
cardiovascular patients. Due to heterogeneity of the
studies, pooling of the data was considered
unjustified.
Results
We found 12 studies examining smoking cessation
interventions in patient populations suffering from
CVD. In the following sections, a description of each
intervention type is given, followed by evidence of its
effectiveness in cardiovascular patient populations.
Pharmacological interventions
Nicotine replacement therapy
Nicotine Replacement Therapy (NRT) is the most
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frequently used pharmacological intervention. It
reduces the severity of physiological withdrawal
symptoms, by replacing the nicotine obtained from
cigarettes, and as such helps to first handle the
psychosocial aspect of withdrawal.33 NRT is available
as chewing gum, transdermal patches, nasal spray or
inhaler.34
Two studies considered the effectiveness of NRT
among cardiovascular patients (Table 1).35,36 No
significant differences between NRT and placebo
were found. Joseph et al.36 assumed that reasons for
the lack of efficacy in their study were, for instance,
patients being of older age, having (a history of)
psychiatric disorder or failing multiple attempts of
quitting.
Other pharmacological interventions
Various other drugs have been tested for assisting
smoking cessation. Smoking cessation lowers levels of
dopamine, serotonine and norepinephrine and, as a
consequence, may cause symptoms such as anxiety
and depression. Anxiolytics and antidepressants37,38
may substitute for these effects. Drugs with anxiolytic
properties are buspirone, diazepam, meprobamate,
ondansetron or beta-blockers. Antidepressants used in
trials are bupropion, doxepin, fluoxetine, imipramine,
moclobemide, nortriptyline, tryptophan, selegline,
sertraline and venlafaxine. Other drugs for smoking
cessation are clonidine39 (lowers bloodpressure),
mecamylamine40 (a nicotine antagonist), lobeline41 (a
nicotine antagonist) and silver acetate42 (an aversive
stimulus).
No studies were found in which cardiovascular
patients were offered anxiolytics, antidepressants or
other agents.
Behavioral interventions
Behavioral intervention programs have varied greatly
in terms of their content and provision. These
programs range from self-help methods, brief thera-
pist-delivered interventions, such as advice from a
physician, to more intensive or tailored behavioral
interventions, such as group therapy or individual
counseling.
Self help
Many smokers prefer to quit smoking individually
instead of participating in a cessation supportive
program.43 Provision of materials (mostly written)
and information can assist them.
In one study,44 by Rice et al. self-help materials were
offered to cardiovascular patients (Table 2). They44
found a significant, but unexpected effect: offering a
self-help booklet was less effective than offering
standard treatment. An explanation for this finding
lies probably in the high refusal rate in the standard
treatment-control-group, which could indicate strong
self-selection.
Physician advice
Advice is defined as verbal instructions from the
physician with a ‘quit smoking’ message irrespective
of whether or not information is provided about the
harmful effects of smoking.45
We found one trial46 in the Cochrane Review45 that
addresses the question whether physician’s advice
contributes to smoking cessation in cardiovascular
patients (Table 3). Burt et al.46 did not examine the
effect of advice vs. standard treatment, but considered
the effects of more intensive advice vs. an advice only
control. The trial showed minimal advice to be more
effective than intensive advice. In this study, no
objective abstinence measures to verify the high (67%
vs. 28%) self-reported abstinence of the patients were
used. Therefore, the authors may have overestimated
the proportion of actual quitters.
Nursing interventions
Nurses frequently advise patients to improve their
health by quitting smoking. Six trials44,47 – 51 focused
on nurse-delivered cessation interventions in cardio-
vascular patients (Table 4). These interventions were in
the form of a brief advice, or involved more intensive
counseling (including increasing motivation to quit;
assisting a quit attempt or help recent quitters to avoid
relapse).
In four of these six trials, significant effects were
found. Taylor et al.50 showed a large positive effect of
the nursing intervention. In this study, some smoking
patients had been encouraged to use NRT. Exclusion of
these patients did not alter the significant effect of
intervention. In the study of Carlsson et al.48 the nurse-
delivered cessation instruction was successful as part
of a multifactorial intervention in cardiovascular
hospitalized patients. However, they did not use
biochemical validation of quitting. Moreover, this
study was very small and showed wide confidence
intervals. Rice et al.44 on the other hand, reported a
significant negative effect of the intervention. As an
explanation, they suggested that smokers who had
experienced coronary bypass surgery were more likely
to quit. These patients were over-represented in the
control group who received advice to quit but no
structured nurse-delivered intervention. Miller et al.49
reported on the effect of the interventions in smokers
with different diagnoses. Interestingly their data
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showed that in CVD patients, the intervention
increased the 12-month quit rate from 24 to 31%,
whereas in other patients, the rates were increased
from 19 to 21%. This might be due to the fact that
different diagnoses may lead to more or less motiv-
ation to make a quit attempt.52
Group and individual counseling
Smokers who find it difficult to quit smoking can seek
help in a formal, organized smoking-cessation pro-
gram. Within such programs, smokers are frequently
treated in groups.53 This is partly for reasons of
efficiency, and partly because it is believed that
group members can motivate each other. Some
programs offer counseling on the basis of an individ-
ual approach.54 Smokers who receive a treatment on a
one to one basis may benefit from exclusive attention
and a tailored approach.
The only study44 that examined group counseling
among cardiovascular patients (Table 5) produced
higher quit rates in the control arm than in the more
intensive individual or group treatment conditions.
The authors explained this counterintuitive finding by
the presence of a disproportionate number of coronary
artery bypass graft (CABG) patients in the control
group. It is possible that the experience of having
CABG surgery contributed to higher cessation rates.
Individual counseling was defined as more than
10 min face-to-face encounter between a patient and
a counselor trained in assisting smoking cessation.54
Counseling could involve one or multiple sessions.
Support offered to the control group ranged from
usual care up to 10 min of advice, with or without the
provision of self-help materials. We found five
studies44,55 – 58 in which the efficacy of individual
behavioral interventions was examined within cardi-
ovascular patients (Table 6). All but the study of
Schmitz et al.58 compared individual counseling to
standard treatment. Schmitz et al. compared two
interventions and without including a standard treat-
ment control group. Only one of these studies in
cardiovascular patients showed a significant differ-
ence between counseling and standard treatment. Rice
et al.44 reported a negative effect of the intervention,
Table 1. Effectiveness of nicotine replacement therapy (NRT) versus placebo.
Study Year Patients Follow-up Treatment NRT* Placebo* ARR (95% CI)
Campbell et al.35 1991 Hospital inpatients
with heart diseases
12 months þ biochemical
validation
1. NRT
2. Placebo gum
15/44 12/41 0.05 (20.15; 0.25)
Joseph et al.36 1996 Outpatients with
cardiovascular diseases
6 months þ biochemical
validation
1. NRT
2. Placebo patch
28/294 35/290 20.03 (20.03; 0.08)
ARR, absolute risk reduction.
*Numbers of quitters relative to total number of patients per condition.
Table 2. Effectiveness of self-help versus standard treatment.
Study Year Patients Follow-up Treatment Self-help* Standard* ARR (95% CI)
Rice et al.44 1994 Outpatients with a
cardiovascular
health problem
12 months þ biochemical
validation
1. Booklet
2. Usual care
3. Booklet þ individual
counseling
3/62† 16/48‡ 20.29 (0.14; 0.43)
4. Booklet þ group
meetings
ARR, absolute risk reduction.
*Numbers of quitters relative to total number of patients per condition.
†Condition 1.
‡Condition 2.
Table 3. Effectiveness of minimal versus intensive physicians’ advice.
Study Year Patients Follow-up Treatment Intensive* Minimal* ARR (95% CI)
Burt et al.46 1974 Outpatients, survivors of
acute myocardial infarction
12 months 1. Intensive advice
2. Minimal advice
27/98 79/125 20.36 (0.23; 0.48)
ARR, absolute risk reduction.
*Numbers of quitters relative to total number of patients per condition.
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meaning that cardiovascular patients receiving stan-
dard treatment were more likely to quit smoking than
patients receiving individual counseling.
Telephone counseling
Telephone services can provide information and
support for smokers through so-called ‘help-lines’,
which are either proactive (counselor initiates) or
reactive (smoker initiates),59,60 and can be adapted to
the needs of the smoker. No trials were found in which
the effect of telephone counseling in cardiovascular
patients was examined.
Discussion
Despite awareness that smoking cessation substan-
tially contributes to the decrease of cardiovascular
events, evidence for effective cessation strategies in
cardiovascular patient populations is very limited. We
found only 12 trials of which five found the intervention
Table 4. Effectiveness of nursing interventions versus standard treatment.
Study Year Patients Follow-up Treatment Nursing
intervention*
Standard* ARR (95% CI)
Taylor et al.50 1990 Inpatients following
acute myocardial
infarction
12 months þ
biochemical
validation
1. Intensive
intervention
2. Usual care
47/84 20/82 0.32 (0.18; 0.46)
Rigotti et al.51 1994 Inpatients scheduled
for coronary artery
bypass surgery
12 months þ
biochemical
validation
1. Intensive
intervention
2. Usual care
22/44 22/43 20.01 (20.20; 0.22)
Rice et al.44 1994 Outpatients with
cardiovascular
disease
12 months þ
biochemical
validation
1. Group
counseling
þ booklet
21/145† 16/48‡ 20.19 (0.04; 0.33)
2. Individual
counseling
þ booklet
3. Booklet
4. Usual care
Allen et al.47 1996 Female post coronary
artery bypass graft
inpatients
12 months 1. Intensive
intervention
2. Usual care
9/14 8/11 20.08 (20.28; 0.45)
Carlsson et al.48 1997 Outpatients, survivors
of acute myocardial
infarction
12 months 1. Intensive
intervention
2. Usual care
16/32 9/35 0.24 (0.02; 0.47)
Miller et al.49 1997 Inpatients with
cardiovascular
disease
12 months 1. Intensive
intervention
2. Minimal
intervention
3. Usual Care
100/320† 74/310§ 0.07 (0.00; 0.14)
ARR, absolute risk reduction.
*Numbers of quitters relative to total number of patients per condition.
†Condition 1 þ 2.
‡Condition 4.
§Condition 3.
Table 5. Effectiveness of group counseling versus standard treatment.
Study Year Patients Follow-up Treatment Group
therapy*
Standard* ARR (95% CI)
Rice et al.44 1994 Outpatients with
cardiovascular
disease
12 months þ biochemical
validation
1. Group counseling þ
booklet
2. Individual counseling þ
booklet
12/82† 16/48‡ 20.19 (0.03; 0.34)
3. Booklet
4. Usual care
ARR, absolute risk reduction.
*Numbers of quitters relative to total number of patients per condition.
†Condition 1.
‡Condition 4.
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to be effective. Many studies suffered from the
inclusion of small numbers of patients and accord-
ingly showed too wide confidence intervals. Therefore
conclusions concerning the effectiveness of interven-
tions in this patient population can only be tentative.
NRT, without additional support, does apparently
not contribute to cessation in cardiovascular patients
compared to placebo. In other populations than
cardiovascular patients, the Cochrane Review34
found NRT to increase the chance of quitting about
one and a half to two times. However, since all these
trials have included at least brief advice or behavioral
support, this appears to be the minimum that should
be offered. Following this general evidence of the
Cochrane Review in other populations, we, therefore,
assume that further research in cardiovascular
patients will demonstrate benefits of NRT when
supplemented with support.
It deserves mentioning that there has been concern
about the safety of NRT in smokers with CVD,61
because some of the cardiotoxic effects of smoking are
attributable to nicotine. In spite of this, Joseph et al.36
found no evidence that serious adverse events
were more common in the NRT group, nor have
others.62,63 Hence, NRT can be recommended to stable
cardiovascular patients if used correctly.21 Patients
must be warned that smoking while using a patch or
gum may increase the risk of cardiovascular and toxic
effects. NRT has not been studied extensively in
patients with acute coronary (vascular) syndromes,
and is therefore relatively contraindicated in patients
with unstable CVD.33,64
Other products, such as bupropion and nortripty-
line, have not been studied in cardiovascular patients.
Especially bupropion, under the name Zyban, is now
recommended to different other populations as first
line pharmacotherapy, challenging NRT.24 However,
reports of severe adverse and allergic reactions
including seizures and deaths among healthy volun-
teers raised questions about the safety of bupropion.65,66
Because safety for cardiovascular patients is an
important consideration, additional research into the
relative efficacy and safety of antidepressants or other
agents is required before treatment in cardiovascular
patients can be recommended.
Self-help materials do not add to smoking cessation
Table 6. Effectiveness of individual counseling versus standard treatment.
Study Year Patients Follow-up Treatment Individual
counseling*
Standard* ARR (94% CI)
Ockene et al.56 1992 Inpatients with coronary
artery stenosis,
following
arteriography
12 months þ
biochemical
validation
1. Individual
counseling
2. Minimal care
47/133 34/123 0.08 (20.04; 0.20)
Rice et al.44 1994 Outpatients with
cardiovascular
disease
12 months þ
biochemical
validation
1. Individual
counseling þ
booklet
9/63† 16/48‡ 20.19 (0.03; 0.35)
2. Group
counseling þ
booklet
3. Booklet
4. Usual care
Rigotti et al.51 1997 Patients with
cardiovascular
disease
6 months þ
biochemical
validation
1. Individual
counseling
2. Usual care
25/307 27/308 20.01 (20.04; 0.05)
Schmitz et al.58 1999 Female inpatients with
coronary artery
disease
6 months þ
biochemical
validation
1. Individual
counseling:
coping skills
relapse
prevention§
3/29† 3/24{ 20.02 (20.15; 0.20)
2. Individual
counseling:
health belief
model§
Dornelas et al.55 2000 Inpatients following
acute myocardial
infarction
12 months þ
biochemical
validation
1. Individual
counseling
2. Minimal care
23/54 12/46 0.17 (20.02; 0.35)
ARR, absolute risk reduction.
*Numbers of quitters relative to total number of patients per condition.
†Condition 1.
‡Condition 4.
§A comparison between two counseling methods. No standard treatment control available.
{Condition 2.
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in cardiovascular patients according to the results of
the only study we found.44 The Cochrane Review also
reported limited evidence for the effectiveness of self-
help materials in other populations.67 It was con-
cluded that self-help materials are more effective when
tailored to the individual’s needs and their readiness
to quit, but have no additional benefit when used
alongside other interventions such as NRT or physi-
cian’s advice.
Minimal physicians-delivered smoking cessation
advice is more effective than a more intensive
approach. However, because the standard treatment
‘control’ group in Burt’s study received minimal
advice, there is no evidence that physician’s advice is
significantly better than no advice in cardiovascular
patients. In studies with other populations, however,
brief advice was compared to a standard treatment
control group and appeared effective. About 5% of
smokers quit if asked to do so by the physician.68 Since
advice can be limited to a brief interaction, concern
was expressed about the small proportion of smokers
who routinely receive advice to quit from their
physicians.69 Even though the effectiveness of physi-
cian’s advice is small, if large numbers of physicians
were to offer advice to their patients, this would have a
substantial effect on smoking cessation numbers.70
So far, studies in which nurses provided intensive
counseling to cardiovascular patients show no con-
vincing evidence for future recommendation. Three
out of six trials reported a significant positive effect of
the intervention whereas one trial showed a negative
effect. Further research should investigate whether
content and/or intensity of the actual nursing
interventions in cardiovascular patients need to be
changed in order to become more effective, because
the Cochrane Review reports reasonable evidence that
nursing interventions can be effective in other popu-
lations.71
The usefulness of group or individual approaches
as cessation aids in cardiovascular patient populations
is uncertain. Few trials are available and no evidence
to support these approaches has been found. In other
populations, however, intensive group or individual
cessation supports are equally (cost) effective accord-
ing to the Cochrane Reviews.53,54
Despite the large amount of existing smoking
cessation studies, few trials have focused on cardio-
vascular patient populations. Following the evidence
of these studies, we find most of the results of the
smoking cessation strategies discouraging. Till now,
there is only some evidence for physician’s advice and
nurse-delivered interventions to be effective. Reasons
for the lack of effectiveness of smoking cessation
strategies in cardiovascular patient groups are not
clear.
Several authors reason that patients who smoke and
suffer from symptomatic CVD are highly motivated to
quit smoking.72,73 Patients are familiar with the
diagnosis and course of their disease and aware of
the consequences of their smoking habit.72,74,46 As a
consequence, one might expect that patients’ motiv-
ation to quit should at least be moderate. Therefore, it
is assumed that the main reason for the lack of
effectiveness of smoking cessation interventions ought
not to be the degree of motivation in the cardiovas-
cular patients. Unfortunately, for some patients, a
diagnosis of a CVD will not by itself be sufficient to
motivate them to quit smoking.
Prochaska and DiClemente75,76 have studied the
relationship between motivation and smoking cessa-
tion. They characterized quitting as a process with
smokers classified according to their stage of change
within this process. The patient needs to be ‘ready to
change’ their behavior in order to quit successfully.
Presumably, stage-matched interventions, which are
adapted to the patient’s needs and readiness to
change, will lead to significantly higher rates of long-
term cessation.76,77
Also, many studies have demonstrated that nicotine
addiction is the main impediment to cessation.5 Heavy
smokers have more problems with the experience of
withdrawal, and stronger urges to smoke. Similarly, a
higher prevalence of heavy smoking has been found in
those who continue to smoke or who relapse after a
cardiac event.72 Furthermore, more indirect measures
of addiction, such as duration and ease of the most
recent failed quit attempt78 are associated with
smoking cessation. When patients finally do quit,
most of them relapse after attempting.43
We noticed that hardly any of the 12 eligible studies
assigned patients to intervention groups on the basis
of their level of addiction or readiness to quit smoking.
Miller et al.49 for instance, excluded patients who were
not motivated to quit. Most studies registered the
number of previous quit attempts or determined the
level of nicotine dependence. However, they rarely
reported the influence of these variables on smoking
cessation or on the effect of a particular intervention.
Increased quitting rates are perhaps to be found in
studies where more attention is given to enhance the
patient’s readiness to quit smoking. Furthermore, we
believe that studies that offer a combination of
smoking cessation interventions to cardiovascular
patients may be more successful. We compared a
specific intervention to a standard treatment control in
order to gain insight in the effectiveness of one specific
type of intervention. Hence, we did not review the
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effects of combinations of treatments. Combinations of
interventions, instead of a single approach, may prove
to be more effective.
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